Edwards Lifesciences has received CE Mark approval for expanding the use of the Sapien 3 transcatheter heart valve to patients with severe, symptomatic aortic stenosis at intermediate risk for ...
A Japanese center found that hemolysis was significantly more common after TAVR with the Sapien 3 Ultra Resilia than with its predecessor device, despite the improvement on paravalvular leaks. Annular ...
Edwards Lifesciences Corporation EW recently launched the SAPIEN 3 Ultra RESILIA valve post the FDA approval of the same. The SAPIEN 3 Ultra RESILIA valve comprises the breakthrough RESILIA tissue ...
(UPDATED) CHICAGO, IL—The latest iteration of the FDA-approved balloon-expandable transcatheter aortic valve has proven itself superior to surgery among intermediate-risk patients in a ...
The Edwards SAPIEN 3 Transcatheter Pulmonary Valve (“TPV”) system with Alterra adaptive prestent is indicated for use in the management of pediatric and adult patients with extreme pulmonary ...
NEWBURY, May 8 2024 -- Edwards Lifesciences today announced the UK launch of the SAPIEN 3 Ultra RESILIA valve, the only transcatheter aortic heart valve to incorporate the company’s breakthrough ...
LONDON--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced one-year data highlighting the continued outstanding performance of its SAPIEN 3 Ultra RESILIA valve. The data were presented ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results